University of Miami, Bascom Palmer Eye Institute, Miami, Florida, USA.
University of Texas Medical Branch, Department of Ophthalmology and Visual Sciences, Galveston, Texas, USA.
Surv Ophthalmol. 2019 Sep-Oct;64(5):679-693. doi: 10.1016/j.survophthal.2019.02.004. Epub 2019 Feb 14.
We reviewed literature on adverse reactions to intravenous fluorescein angiography using PubMed and found 78 articles in English from 1961 to 2017. The reported rates of adverse reactions were overall 0.083-21.69%, separated into mild (1.24-17.65%), moderate (0.2-6%), and severe (0.04-0.59%). There were 1:100,000 to 1:220,000 deaths. Fluorescein concentration, volume injected, speed of injection, temperature, and contaminants were not correlated with the incidence of reactions. Patient characteristics including other comorbid diseases, allergy history, age, race, and gender showed only an increased rate of reaction in patients with a history of reaction to fluorescein. Although a number of studies examine techniques to reduce adverse reactions to intravenous fluorescein angiography, to date, the only proven method is reviewing allergy history, specifically a history of previous reaction to fluorescein.
我们使用 PubMed 回顾了静脉注射荧光素血管造影不良反应的文献，发现从 1961 年到 2017 年有 78 篇英文文章。报告的不良反应发生率总体为 0.083-21.69%，分为轻度（1.24-17.65%）、中度（0.2-6%）和重度（0.04-0.59%）。有 1:100000 至 1:220000 的死亡病例。荧光素浓度、注射量、注射速度、温度和污染物与反应发生率无关。患者特征，包括其他合并症、过敏史、年龄、种族和性别，仅在有荧光素过敏史的患者中显示出反应发生率增加。尽管许多研究都在探讨降低静脉注射荧光素血管造影不良反应的技术，但迄今为止，唯一被证实的方法是审查过敏史，特别是对荧光素的既往反应史。
